Regulation of CD44 Gene Expression by the Proinflammatory Cytokine Interleukin-1β in Vascular Smooth Muscle Cells

Lauren C. Foster, Burak M. Arkonac, Nicholas Sibinga, Chengwei Shi, Mark A. Perrella, Edgar Haber

Journal of Biological Chemistry · 1998 · 52 citations · 43 references

DOIFull text

Open access

Concepts

Abstract

The CD44 gene codes for a family of alternatively spliced, multifunctional adhesion molecules that participate in extracellular matrix binding, lymphocyte activation, cell migration, and tumor metastasis. In a mouse model of transplant-associated arteriosclerosis, CD44 protein was induced in the neointima of allografted vessels and colocalized with a subset of proliferating vascular smooth muscle cells (SMC). To elucidate the molecular mechanisms regulating CD44 expression in this model, we investigated the regulation of CD44 gene expression by interleukin (IL)-1β. Treatment of rat aortic SMC with IL-1β resulted in a 5.3-fold increase in cell surface CD44 expression. Northern analysis showed that IL-1β promoted a dose- and time-dependent induction of CD44 mRNA which reached 6.6-fold after 48 h, and nuclear run-on analysis showed that IL-1β increased the rate of CD44 gene transcription within 8 h of stimulation. In transient reporter gene transfection experiments in rat aortic SMC, a 1.4-kilobase fragment of the mouse CD44 5′-flanking sequence mediated this response to IL-1β. Regulation of CD44 gene expression by the proinflammatory cytokine IL-1β may contribute to SMC phenotypic modulation in the pathogenesis of arteriosclerosis. The CD44 gene codes for a family of alternatively spliced, multifunctional adhesion molecules that participate in extracellular matrix binding, lymphocyte activation, cell migration, and tumor metastasis. In a mouse model of transplant-associated arteriosclerosis, CD44 protein was induced in the neointima of allografted vessels and colocalized with a subset of proliferating vascular smooth muscle cells (SMC). To elucidate the molecular mechanisms regulating CD44 expression in this model, we investigated the regulation of CD44 gene expression by interleukin (IL)-1β. Treatment of rat aortic SMC with IL-1β resulted in a 5.3-fold increase in cell surface CD44 expression. Northern analysis showed that IL-1β promoted a dose- and time-dependent induction of CD44 mRNA which reached 6.6-fold after 48 h, and nuclear run-on analysis showed that IL-1β increased the rate of CD44 gene transcription within 8 h of stimulation. In transient reporter gene transfection experiments in rat aortic SMC, a 1.4-kilobase fragment of the mouse CD44 5′-flanking sequence mediated this response to IL-1β. Regulation of CD44 gene expression by the proinflammatory cytokine IL-1β may contribute to SMC phenotypic modulation in the pathogenesis of arteriosclerosis. Vascular smooth muscle and the associated connective tissue matrix are central to blood vessel integrity and function, and activation of vascular smooth muscle cells is characteristic of arteriosclerosis and hypertension. After vessel wall injury, smooth muscle cells are transformed from a contractile, quiescent phenotype to a proliferative, migratory phenotype that secretes abundant extracellular matrix (1Raines E.W. Ross R. Br. Heart J. 1993; 69: S30-S37Crossref PubMed Scopus (304) Google Scholar). Vascular smooth muscle cells are subject to complex regulation by soluble extracellular signals provided by growth factors, cytokines, and vasoactive agents as well as cell-cell and cell-matrix interactions (1Raines E.W. Ross R. Br. Heart J. 1993; 69: S30-S37Crossref PubMed Scopus (304) Google Scholar). Therefore, factors controlling smooth muscle cell behavior, including migration, proliferation, and lipid metabolism, are critical to the pathogenesis of cardiovascular disease. Cell surface signal transduction and adhesion molecules such as vascular cell adhesion molecule-1 (2O'Brien K.D. Allen M.D. McDonald T.O. Chait A. Harlan J.M. Fishbein D. McCarthy J. Ferguson M. Hudkins K. Benjamin C.D. Lobb R. Alpers C.E. J. Clin. Invest. 1993; 92: 945-951Crossref PubMed Scopus (632) Google Scholar) and the β1 and β3 integrins (3Clyman R.I. Mauray F. Kramer R.H. Exp. Cell Res. 1992; 200: 272-284Crossref PubMed Scopus (167) Google Scholar, 4Skinner M.P. Raines E.W. Ross R. Am. J. Pathol. 1994; 145: 1070-1081PubMed Google Scholar) have been implicated in the modulation of smooth muscle cell function. Previous studies from our laboratory indicate that the proteoglycan CD44 may also mediate vascular smooth muscle cell activation during vascular remodeling (5Jain M. He Q. Lee W.-S. Kashiki S. Foster L.C. Tsai J.-C. Lee M.-E. Haber E. J. Clin. Invest. 1996; 97: 596-603Crossref PubMed Scopus (98) Google Scholar). The CD44 transmembrane glycoprotein exists in a variety of isoforms generated by alternative splicing of one (or more) of 10 variable exons in the extracellular domain (6Screaton G.R. Bell M.V. Jackson D.G. Cornelis F.B. Gerth U. Bell J.I. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 12160-12164Crossref PubMed Scopus (974) Google Scholar, 7Gunthert U. Curr. Top. Microbiol. Immunol. 1993; 184: 47-63Crossref PubMed Scopus (245) Google Scholar). CD44 is the principal cell receptor for hyaluronic acid (8Aruffo A. Stamenkovic I. Melnick M. Underhill C.B. Seed B. Cell. 1990; 61: 1303-1313Abstract Full Text PDF PubMed Scopus (2123) Google Scholar) and interacts with other extracellular matrix molecules including osteopontin, collagen, and fibronectin (9Weber G.F. Ashkar S. Glimcher M.J. Cantor H. Science. 1996; 271: 509-512Crossref PubMed Scopus (800) Google Scholar, 10Lesley J. Hyman R. Kincade P. Adv. Immunol. 1993; 54: 271-335Crossref PubMed Scopus (1025) Google Scholar). Present on many cell types, CD44 has been correlated with cell proliferation (11Alho A.M. Underhill C.B. J. Cell Biol. 1989; 108: 1557-1565Crossref PubMed Scopus (193) Google Scholar, 12Lazaar A.L. Albelda S.M. Pilewski J.M. Brennan B. Pure E. Panettieri Jr., R.A. J. Exp. Med. 1994; 180: 807-816Crossref PubMed Scopus (210) Google Scholar) and oncogenic transformation (13Hofmann M. Rudy W. Gunthert U. Zimmer S.G. Zawadzki V. Zoller M. Lichtner R.B. Herrlich P. Ponta H. Cancer Res. 1993; 53: 1516-1521PubMed Google Scholar). Ligation of CD44 stimulates cytokine release by monocytes/macrophages (14Webb D.S.A. Shimizu Y. Van Seventer G.A. Shaw S. Gerrard T.L. Science. 1990; 249: 1295-1297Crossref PubMed Scopus (275) Google Scholar, 15Noble P.W. Lake F.R. Henson P.M. Riches D.W.H. J. Clin. Invest. 1993; 91: 2368-2377Crossref PubMed Scopus (305) Google Scholar), and it may modulate T lymphocyte activation signals (16Shimizu Y. Van Seventer G.A. Siraganian R. Wahl G. Shaw S. J. Immunol. 1989; 143: 2457-2463PubMed Google Scholar, 17Pierres A. Lipcey C. Mawas C. Olive D. Eur. J. Immunol. 1992; 22: 413-417Crossref PubMed Scopus (47) Google Scholar). In a variety of cell systems CD44 imparts a novel cellular adhesive and/or migratory phenotype to transfected cells (9Weber G.F. Ashkar S. Glimcher M.J. Cantor H. Science. 1996; 271: 509-512Crossref PubMed Scopus (800) Google Scholar, 18St. John T. Meyer J. Idzerda R. Gallatin W.M. Cell. 1990; 60: 45-52Abstract Full Text PDF PubMed Scopus (115) Google Scholar, 19Thomas L. Byers H.R. Vink J. Stamenkovic I. J. Cell Biol. 1992; 118: 971-977Crossref PubMed Scopus (299) Google Scholar), and an isoform containing the sixth variable exon (v6) confers metastatic potential to rat pancreatic carcinoma cells (20Gunthert U. Hofmann M. Rudy W. Reber S. Zoller M. Haubmann I. Matzku S. Wenzel A. Ponta H. Herrlich P. Cell. 1991; 65: 13-24Abstract Full Text PDF PubMed Scopus (1584) Google Scholar). The importance of CD44 in vivo has also been demonstrated in a mouse model in which an antisense CD44 transgene is expressed selectively under the control of a keratinocyte-specific promoter (21Kaya G. Rodriguez I. Jorcano J.L. Vassalli P. Stamenkovic I. Genes Dev. 1997; 11: 996-1007Crossref PubMed Scopus (219) Google Scholar). Suppression of CD44 expression inhibits keratinocyte proliferation and results in abnormal hyaluronate metabolism in the skin. Moreover, CD44 is induced on smooth muscle cells after vascular injury, and it may mediate the proliferative effects of hyaluronate (5Jain M. He Q. Lee W.-S. Kashiki S. Foster L.C. Tsai J.-C. Lee M.-E. Haber E. J. Clin. Invest. 1996; 97: 596-603Crossref PubMed Scopus (98) Google Scholar). Our laboratory has developed a mouse model of transplant-associated arteriosclerosis in which a carotid artery loop is transplanted between inbred strains in syngeneic and allogeneic combinations (22Shi C. Russell M.E. Bianchi C. Newell J. Haber E. Circ. Res. 1994; 75: 199-207Crossref PubMed Scopus (79) Google Scholar). Lesion development depends on an acquired immune response and begins with infiltration of inflammatory cells, after which follows accumulation of smooth muscle cells in the neointima (23Shi C. Lee W.S. He Q. Zhang D. Fletcher D.L. Newell J.B. Haber E. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 4051-4056Crossref PubMed Scopus (188) Google Scholar). In the present study we evaluated CD44 cell surface protein expression in vivoduring the pathogenesis of transplant arteriosclerosis in order to understand the role of CD44 in modulating vascular smooth muscle cell phenotype. To elucidate the molecular mechanisms regulating CD44 expression in vascular smooth muscle cells after injury, we studied the effect of interleukin (IL) 1The abbreviations used are: ILinterleukinRASMCrat aortic smooth muscle cellsPCNAproliferating cell nuclear antigenPBSphosphate-buffered salineCATchloramphenicol acetyltransferasekbkilobase(s).1The abbreviations used are: ILinterleukinRASMCrat aortic smooth muscle cellsPCNAproliferating cell nuclear antigenPBSphosphate-buffered salineCATchloramphenicol acetyltransferasekbkilobase(s). 1β on CD44 gene expression in cultured rat aortic smooth muscle cells (RASMC). interleukin rat aortic smooth muscle cells proliferating cell nuclear antigen phosphate-buffered saline chloramphenicol acetyltransferase kilobase(s). interleukin rat aortic smooth muscle cells proliferating cell nuclear antigen phosphate-buffered saline chloramphenicol acetyltransferase kilobase(s). Carotid artery transplantation was performed as described (22Shi C. Russell M.E. Bianchi C. Newell J. Haber E. Circ. Res. 1994; 75: 199-207Crossref PubMed Scopus (79) Google Scholar). In brief, a carotid artery loop was transplanted between two strains of inbred mice incompatible in the H-2 region. B.10A(2R) (H-2h2) mice were used as donors in the allograft group, and C57BL/6J (H-2b) mice were used as donors in the isograft group. C57BL/6J (H-2b) mice were used as recipients in both groups. Transplant samples were prepared and immunostained as described by Shi et al. (22Shi C. Russell M.E. Bianchi C. Newell J. Haber E. Circ. Res. 1994; 75: 199-207Crossref PubMed Scopus (79) Google Scholar). Grafts were harvested and processed in methyl Carnoy's fixative, embedded in paraffin, and cut in a microtome in 4-μm cross-sections. After removal of the paraffin, tissue sections were incubated with 10% normal serum for 20 min at room temperature. Immunohistochemical analysis for CD44 was carried out with a rat anti-mouse CD44 monoclonal antibody (IM7, rat IgG2b, 1 μg/ml; PharMingen, San Diego, CA). Proliferating cells were detected with a proliferating cell nuclear antigen (PCNA) antibody (clone PC10, 3 μg/ml; Oncogene Research Products, Cambridge, MA), and vascular smooth muscle cells with an anti-smooth muscle actin monoclonal antibody (anti-NH2-terminal decapeptide, clone 1A4, 1:400; Sigma). Tissue samples were incubated with the antibodies at room temperature for 1 h and then at 4 °C overnight. Biotinylated rabbit anti-rat IgG (1:100, Vector Laboratories, Burlingame, CA) was used as a secondary antibody to detect CD44 staining, and biotinylated goat anti-mouse IgG2a antibody (RPN 1181, 1:100, Amersham Pharmacia Biotech) was used as a secondary antibody to detect PCNA and α-actin staining. Sections stained for CD44 and PCNA were labeled with avidin-biotin enzyme complex peroxidase (Vector Laboratories) and developed in 3,3′-diaminobenzidine. Sections stained for α-actin were labeled with avidin-biotin enzyme complex alkaline phosphatase and developed with VectorRed (Vector Laboratories). Sections treated for CD44 and PCNA were counterstained with 1% methyl green, and sections treated for α-actin were counterstained with Verhoeff's stain for elastic tissue. RASMC were harvested from the thoracic aorta of adult male Sprague-Dawley rats (200–250 g) by enzymatic dissociation according to the method of Gunther et al. (24Gunther S. Alexander R.W. Atkinson W.J. Gimbrone Jr., M.A. J. Cell Biol. 1982; 92: 289-298Crossref PubMed Scopus (277) Google Scholar). The cells were cultured in Dulbecco's modified Eagle's medium (JRH Biosciences, Lenexa, KS) and supplemented with 10% fetal calf serum, penicillin (100 units/ml), streptomycin (100 μg/ml), and 25 mm Hepes (pH 7.4). RASMC were passaged every 4–7 days, and experiments were performed on cells four to seven passages from primary culture. Recombinant IL-1β and platelet-derived growth factor-BB were obtained from Collaborative Biomedical (Bedford, MA). Tumor necrosis factor-α and interferon-γ were obtained from Life Technologies, Inc. Cultured RASMC were treated with vehicle or IL-1β (10 harvested with mm in phosphate-buffered saline and in serum in were incubated with antibody or mouse IgG2a control antibody CA) for min at 4 cells were with serum in and incubated with secondary antibody anti-mouse analysis was performed on an CA) with a and analysis was obtained from cultured cells by and J. T. Scholar). The was on a and to The were with a rat CD44 as described (5Jain M. He Q. Lee W.-S. Kashiki S. Foster L.C. Tsai J.-C. Lee M.-E. Haber E. J. Clin. Invest. 1996; 97: 596-603Crossref PubMed Scopus (98) Google Scholar). The were with at °C or on To for in the were with an The were and was on a the CA). RASMC were treated with or with IL-1β for 8 The cells were then and were as described M.A. M. Tsai J.-C. S. Lee M.-E. J. Biol. 1994; Full Text PDF PubMed Google Scholar). The nuclear was incubated with a of and and with of Life The samples were then with and at in on were at °C for 4 in the of for the CD44 and were used as The were and was on a the The of the CD44 was by that the and the was as a increase from the control fragment of the 5′-flanking of the mouse gene CD44 was by the CA). were according to the mouse CD44 sequence C. G. John T. Proc. Natl. Acad. Sci. U. S. A. 1989; PubMed Scopus Google Scholar, J. Immunol. 1989; 143: Google Scholar). and a were used in the primary and secondary to a fragment from mouse The fragment was and by the method J. T. Scholar) with S. fragment of the mouse CD44 5′-flanking sequence was with and used to a of mouse in the CA) as described C. M.A. M. Lee M.E. Haber E. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). were and and was prepared according to J. T. Scholar). from the mouse CD44 were and with Pharmacia analysis was performed with the analysis to the transcription of the mouse CD44 gene was performed as described C. M.A. M. Lee M.E. Haber E. J. Biol. Full Text Full Text PDF PubMed Scopus Google Scholar). to the 5′-flanking sequence of the mouse CD44 was labeled with and to of which was then to transcription were by on an cells were obtained from the cells were the of CA). the gene with promoter and the chloramphenicol acetyltransferase gene by the containing of the mouse CD44 5′-flanking sequence were according to the of the fragment from the transcription in the and gene fragment from mouse containing of the CD44 5′-flanking sequence and of the transcription was and CD44 fragment containing and of the CD44 transcription was and CD44 of the were generated by and by the method to the and of the RASMC were transfected by a method M.A. C. L. M. Lee M.-E. J. Biol. 1996; 271: Full Text Full Text PDF PubMed Scopus Google Scholar). In brief, cells were tissue and to for h and for in transfection were to RASMC in a containing of RASMC were then with a for 1 min and to in medium containing 10% fetal calf h after RASMC were in fetal calf serum and with vehicle or IL-1β (10 for 48 Cell were prepared by a method and was in for samples by the and an The was performed by a modified method as described M.A. C. L. M. Lee M.-E. J. Biol. 1996; 271: Full Text Full Text PDF PubMed Scopus Google Scholar). The of to in as a of was transfected at and for are as the in treated with vehicle was with that in treated with IL-1β by analysis of was at To understand CD44 may modulate vascular smooth muscle cell phenotype during vascular we studied CD44 expression in a mouse model of transplant-associated arteriosclerosis. analysis was performed on sections from allografted and carotid harvested at after a at which is (22Shi C. Russell M.E. Bianchi C. Newell J. Haber E. Circ. Res. 1994; 75: 199-207Crossref PubMed Scopus (79) Google Scholar). sections CD44 protein expression in the neointima 1 sections showed CD44 expression and neointima 1 The of proliferation cells, as by for PCNA was in allograft PCNA was in the isograft control that CD44 and PCNA a of induction in the neointima in allografted Vascular smooth muscle cells in the as by for smooth muscle α-actin 1 that proliferating vascular smooth muscle cells for the of CD44 expression in the neointima during the development of transplant-associated arteriosclerosis. To signals regulating CD44 expression in vascular smooth muscle cells, we the effect of the proinflammatory cytokine IL-1β on CD44 protein and mRNA RASMC were cultured in fetal calf serum and treated with IL-1β (10 for 48 Cell surface CD44 expression was then by antibody and CD44 surface antigen was present on RASMC under and increased by 5.3-fold after IL-1β stimulation. then performed Northern analysis with from RASMC treated with vehicle or IL-1β and with a rat CD44 The CD44 mRNA and showed four at and to for CD44 (5Jain M. He Q. Lee W.-S. Kashiki S. Foster L.C. Tsai J.-C. Lee M.-E. Haber E. J. Clin. Invest. 1996; 97: 596-603Crossref PubMed Scopus (98) Google Scholar). isoforms are to from alternative splicing of exons or from the of In the Northern of the of CD44 mRNA induction an IL-1β of 10 increased CD44 mRNA as as h after stimulation. CD44 mRNA induction reached 6.6-fold after 48 In a induction of CD44 mRNA was in RASMC for h with of IL-1β 3 increase in CD44 mRNA was at an IL-1β of as as 1 and at a of 10 the of an IL-1β of 10 was used in The of IL-1β to increase the of CD44 mRNA was in the of the protein and that was of protein indicate that the cytokine IL-1β as a to CD44 protein and mRNA expression in To the of the effect of IL-1β on CD44 gene we the of other and growth factors implicated in the development of to modulate CD44 mRNA expression. RASMC were treated with tumor necrosis and platelet-derived growth factor-BB for of and the CD44 was by Northern analysis Tumor necrosis an inflammatory cytokine effects are to of promoted a increase in CD44 mRNA which reached at 48 which inhibits vascular smooth muscle cell growth J. 1991; PubMed Scopus Google Scholar, P. J. Clin. Invest. 1989; PubMed Scopus Google Scholar) stimulates J.L. Russell P.W. J. Immunol. Google Scholar) and lymphocyte P.W. PubMed Scopus Google Scholar, M. A. P. PubMed Scopus Google Scholar) activation, a effect on CD44 growth a and for smooth muscle cells, a induction of CD44 mRNA at 4 h which to by In of this we our on which a and induction of CD44 in vascular smooth muscle To elucidate the by which IL-1β CD44 we performed nuclear run-on experiments to the effect of IL-1β on the rate of CD44 gene CD44 mRNA transcription in RASMC increased by within 8 h of IL-1β with control of RASMC to IL-1β the of CD44 mRNA in the of the transcription which was 48 h To the mechanisms regulating the expression of CD44 in vascular smooth muscle cells, we the of the mouse CD44 used sequence from a fragment of the mouse CD44 gene with the to a fragment of CD44 5′-flanking sequence from mouse the sequence of the mouse CD44 then the transcription of the mouse CD44 gene by to CD44 to with was used to gene transcription on from and the cell was in cells, from a transcription to a of the of results were obtained with from mouse aortic smooth muscle cells and were with an to transcription by studies was with results obtained by analysis the CD44 a a for transcription for activation of transcription an is present D. Proc. Natl. Acad. Sci. U. S. A. 1990; PubMed Scopus Google Scholar). of the mouse CD44 with in the a variety of including and as well as a a and a response analysis also an at which is in the CD44 promoter (13Hofmann M. Rudy W. Gunthert U. Zimmer S.G. Zawadzki V. Zoller M. Lichtner R.B. Herrlich P. Ponta H. Cancer Res. 1993; 53: 1516-1521PubMed Google Scholar). reporter by and of the CD44 5′-flanking sequence to CD44 promoter in in were RASMC with and was expressed as a of in The promoter of CD44 increased by with IL-1β IL-1β a increase in the of CD44 which that the IL-1β are in the to fragment of the CD44 5′-flanking The to fragment in the antisense that was by with IL-1β In with the nuclear run-on experiments that the induction of CD44 mRNA by IL-1β is to a In a variety of cell have been for CD44 in cellular activation and that are central to the smooth muscle cell response to wall In our mouse model of transplant-associated arteriosclerosis, CD44 is expressed in the of the normal vascular wall in vivo and is induced on smooth muscle cells in the neointima of allografted carotid In extracellular matrix for including hyaluronate and osteopontin, are in and may in modulating vascular smooth muscle cell (5Jain M. He Q. Lee W.-S. Kashiki S. Foster L.C. Tsai J.-C. Lee M.-E. Haber E. J. Clin. Invest. 1996; 97: 596-603Crossref PubMed Scopus (98) Google Scholar, R. C. C. J.M. 1996; 93: PubMed Scopus Google Scholar, M. Alpers C.E. S.M. J. Clin. Invest. 1993; 92: PubMed Scopus Google Scholar). The expression of the CD44 adhesion receptor and may such as smooth muscle cell and during vascular CD44 expression has been in a variety of cell types, is the molecular regulation of the CD44 CD44 transcription is in rat in an and expression with cellular metastatic potential (13Hofmann M. Rudy W. Gunthert U. Zimmer S.G. Zawadzki V. Zoller M. Lichtner R.B. Herrlich P. Ponta H. Cancer Res. 1993; 53: 1516-1521PubMed Google Scholar). growth a novel to CD44 expression in mouse which is by cell to hyaluronic acid M. A. J. Biol. 1997; Full Text Full Text PDF PubMed Scopus Google Scholar). In the of lymphocyte activation during immune the CD44 promoter is by the transcription after cell antigen receptor Cell. Biol. 1996; PubMed Scopus Google Scholar). Our present studies the mechanisms by which CD44 gene expression in vascular smooth muscle and growth factors cellular that are central to including proliferation, lipid metabolism, and of extracellular matrix (1Raines E.W. Ross R. Br. Heart J. 1993; 69: S30-S37Crossref PubMed Scopus (304) Google Scholar, J. Res. 1993; PubMed Scopus Google Scholar). The proinflammatory cytokine IL-1β is present in and in cellular gene expression which with the development of smooth muscle cell D. H. Am. J. Pathol. 1991; Google Scholar). IL-1β is for vascular smooth muscle E. C. F. P. 1993; Full Text PDF PubMed Scopus Google Scholar, P. J. Clin. Invest. PubMed Scopus Google Scholar), and it to the regulation of cytokine extracellular matrix adhesion and matrix by cells Proc. Natl. Acad. Sci. U. S. A. 1991; PubMed Scopus Google Scholar, S. M. J. Cell. PubMed Scopus Google Scholar, T. C. C. J. Circ. Res. 1994; PubMed Scopus Google Scholar, M. G. E. E. P. Circ. Res. 1994; 75: PubMed Scopus Google Scholar). that of primary cultured RASMC with IL-1β induced CD44 protein and which was to an increase in the rate of CD44 gene transfection experiments in RASMC showed that induction by IL-1β was mediated by that within a fragment of the mouse CD44 that IL-1β induction of CD44 gene expression to a response of smooth muscle cells to wall the control of the CD44 promoter may elucidate mechanisms that modulate smooth muscle cell phenotype in the pathogenesis of vascular disease. our to Lee for the and for this for Zhang for and for The cell was provided by

References

43